What is the recommended lidocaine intravenous infusion dose and rate for anti‑arrhythmic therapy?

Lidocaine Infusion Dosing for Anti-Arrhythmic Therapy

For ventricular arrhythmias, initiate lidocaine with a 1 mg/kg IV bolus (maximum 100 mg), followed by a maintenance infusion of 1-4 mg/min (20-50 mcg/kg/min), with dose reduction required in heart failure, elderly patients, and hepatic dysfunction. 1

Loading Dose Protocol

Initial bolus administration:

• Give 1 mg/kg IV bolus (not to exceed 100 mg) 1
• Additional boluses of 0.5 mg/kg can be given every 8-10 minutes if needed, up to a total cumulative dose of 3-4 mg/kg 1
• In cardiac arrest with ventricular fibrillation, use 100 mg bolus every 2-3 minutes as needed 1

Critical timing consideration: Patients may experience transient subtherapeutic plasma concentrations 30-120 minutes after initial bolus, requiring a second 0.5 mg/kg bolus without increasing the maintenance rate 1

Maintenance Infusion Rates

Standard dosing for adults (70 kg patient):

• 20-50 mcg/kg/min (equivalent to 1.4-3.5 mg/min in a 70 kg patient) 1
• The 2010 AHA guidelines specify 1-4 mg/min maintenance infusion 1
• Recent evidence in heart failure patients suggests 1 mg/min achieves the highest probability of therapeutic levels (78.6%) 2

Patients requiring multiple boluses: May need higher maintenance doses up to 40-50 mcg/kg/min 1

Dose Adjustments for High-Risk Populations

Mandatory dose reductions in:

• Heart failure patients: Lidocaine half-life increases to >20 hours (vs. 1-2 hours in normal subjects), requiring significant infusion rate reduction 1
• Cardiogenic shock: Even longer half-life than heart failure alone 1
• Elderly patients (>70 years): Higher risk of toxicity; reduce infusion rates 1
• Hepatic dysfunction: Lidocaine is eliminated almost exclusively by the liver 1

Time-dependent adjustments: After 24-48 hours, lidocaine half-life increases, requiring dose reduction by 1 mg/min preferably at 12 hours but at least by 24 hours 1

Therapeutic Monitoring

Target plasma concentration: 1.5-5.0 mcg/mL 2

• Maintenance infusion of 20-50 mcg/kg/min produces blood levels up to 5 mcg/mL 1
• Toxic levels occur at approximately 9-10 mcg/mL 1

Monitor serum levels when:

• Using prolonged or high infusion rates 1
• Patient develops neurologic changes 1
• Severe renal dysfunction present 1

Toxicity Recognition and Management

CNS toxicity symptoms (most common):

• Perioral numbness, dizziness, confusion, slurred speech 1
• Drowsiness, altered consciousness, muscle twitching 1
• Seizures, respiratory depression or arrest 1, 3

Cardiovascular toxicity:

• Bradycardia, sinus arrest, hypotension 1

Management: Immediate discontinuation of lidocaine, benzodiazepines for seizures, and supportive care 3

Clinical Context and Limitations

Current role: Lidocaine is now considered a second-line agent after amiodarone for shock-refractory VF/pulseless VT, though recent data suggest lidocaine may have superior outcomes in in-hospital cardiac arrest 1, 4

Specific indications for use:

• Hemodynamically stable monomorphic VT 1
• Ventricular arrhythmias refractory to defibrillation 1
• Frequent (>6/min), multiform, or closely coupled ventricular premature beats 1

Important caveat: Prophylactic lidocaine is not recommended in uncomplicated acute MI, as it may increase asystole risk without mortality benefit 1